Effectiveness of the 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 Vaccine (mRNA-1273.815) in Preventing COVID-19-related Hospitalizations and Medical Encounters Among Adults in the United States.

IF 3.8 4区医学 Q2 IMMUNOLOGY

Open Forum Infectious Diseases Pub Date : 2024-11-26 eCollection Date: 2024-12-01 DOI:10.1093/ofid/ofae695

Hagit Kopel, Andre B Araujo, Alina Bogdanov, Ni Zeng, Isabelle Winer, Jessamine P Winer-Jones, Tianyi Lu, Morgan A Marks, Machaon Bonafede, Van Hung Nguyen, David Martin, James A Mansi

{"title":"Effectiveness of the 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 Vaccine (mRNA-1273.815) in Preventing COVID-19-related Hospitalizations and Medical Encounters Among Adults in the United States.","authors":"Hagit Kopel, Andre B Araujo, Alina Bogdanov, Ni Zeng, Isabelle Winer, Jessamine P Winer-Jones, Tianyi Lu, Morgan A Marks, Machaon Bonafede, Van Hung Nguyen, David Martin, James A Mansi","doi":"10.1093/ofid/ofae695","DOIUrl":null,"url":null,"abstract":"Background: This study aimed to evaluate the vaccine effectiveness (VE) of mRNA-1273.815, a 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine, at preventing COVID-19-related hospitalizations and any medically attended COVID-19 in adults.Methods: In a linked electronic health record-claims dataset, we identified US adults (≥18 years) who received the mRNA-1273.815 vaccine (exposed cohort) between 12 September and 15 December 2023, matched 1:1 to individuals who did not receive a 2023-2024 updated COVID-19 vaccine (unexposed cohort). Cohorts were balanced using inverse probability of treatment weighting on demographics, vaccination and infection history, and underlying medical conditions. Study cohorts were followed until 31 December 2023 for COVID-19-related hospitalizations and medically attended COVID-19. Cox regression was used to estimate hazard ratios and VE. Subgroup analyses were performed for adults ≥50 years, adults ≥65 years, and individuals with underlying medical conditions.Results: Overall, 859 335 matched pairs of mRNA-1273.815 recipients and unexposed adults were identified. The mean (standard deviation) age was 63 (16) years. More than 60% of individuals in both cohorts had an underlying medical condition. Among the overall adult population, VE was 60.2% (95% confidence interval, 53.4-66.0) against COVID-19-related hospitalization and 33.1% (30.2-35.9) against medically attended COVID-19 over a median follow-up of 63 (interquartile range: 44-78) days. VE estimates by age and underlying medical conditions were similar.Conclusions: These results demonstrate the significant protection provided by mRNA-1273.815 against COVID-19-related hospitalizations and any medically attended COVID-19 in adults, regardless of vaccination history, and support Centers for Disease Control and Prevention recommendations to stay up-to-date with COVID-19 vaccination to prevent COVID-19-related outcomes, including hospitalizations.","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 12","pages":"ofae695"},"PeriodicalIF":3.8000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11651145/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Forum Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ofid/ofae695","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This study aimed to evaluate the vaccine effectiveness (VE) of mRNA-1273.815, a 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine, at preventing COVID-19-related hospitalizations and any medically attended COVID-19 in adults.

Methods: In a linked electronic health record-claims dataset, we identified US adults (≥18 years) who received the mRNA-1273.815 vaccine (exposed cohort) between 12 September and 15 December 2023, matched 1:1 to individuals who did not receive a 2023-2024 updated COVID-19 vaccine (unexposed cohort). Cohorts were balanced using inverse probability of treatment weighting on demographics, vaccination and infection history, and underlying medical conditions. Study cohorts were followed until 31 December 2023 for COVID-19-related hospitalizations and medically attended COVID-19. Cox regression was used to estimate hazard ratios and VE. Subgroup analyses were performed for adults ≥50 years, adults ≥65 years, and individuals with underlying medical conditions.

Results: Overall, 859 335 matched pairs of mRNA-1273.815 recipients and unexposed adults were identified. The mean (standard deviation) age was 63 (16) years. More than 60% of individuals in both cohorts had an underlying medical condition. Among the overall adult population, VE was 60.2% (95% confidence interval, 53.4-66.0) against COVID-19-related hospitalization and 33.1% (30.2-35.9) against medically attended COVID-19 over a median follow-up of 63 (interquartile range: 44-78) days. VE estimates by age and underlying medical conditions were similar.

Conclusions: These results demonstrate the significant protection provided by mRNA-1273.815 against COVID-19-related hospitalizations and any medically attended COVID-19 in adults, regardless of vaccination history, and support Centers for Disease Control and Prevention recommendations to stay up-to-date with COVID-19 vaccination to prevent COVID-19-related outcomes, including hospitalizations.

查看原文本刊更多论文

2023-2024年含mRNA COVID-19疫苗（mRNA-1273.815）在美国成年人中预防COVID-19相关住院和医疗遭遇的有效性

背景：本研究旨在评估mRNA-1273.815（含2023-2024 Omicron xbb .1.5的mRNA- COVID-19疫苗）在预防成人COVID-19相关住院和任何就诊的疫苗有效性（VE）。方法：在相关的电子健康记录声明数据集中，我们确定了在2023年9月12日至12月15日期间接种mRNA-1273.815疫苗（暴露队列）的美国成年人（≥18岁），与未接种2023-2024年更新的COVID-19疫苗的个体（未暴露队列）进行1:1匹配。使用人口统计学、疫苗接种和感染史以及潜在医疗条件的治疗加权逆概率来平衡队列。对研究队列进行随访，直至2023年12月31日，以了解与COVID-19相关的住院情况和接受医疗的COVID-19。采用Cox回归估计风险比和VE。对≥50岁的成年人、≥65岁的成年人和有潜在疾病的个体进行亚组分析。结果：总共鉴定出859 335对mRNA-1273.815受体和未暴露的成年人。平均（标准差）年龄为63（16）岁。在这两个队列中，超过60%的人有潜在的医疗状况。在整个成年人群中，在中位随访63天（四分位数间距：44-78）内，与COVID-19相关的住院治疗的VE为60.2%(95%置信区间：53.4-66.0)，而在医学上参加COVID-19治疗的VE为33.1%（30.2-35.9）。按年龄和基本医疗条件划分的VE估计值相似。结论：这些结果表明，mRNA-1273.815对与COVID-19相关的住院治疗和任何就医的成人COVID-19提供了显著的保护，无论疫苗接种史如何，并支持疾病控制和预防中心的建议，即及时接种COVID-19疫苗，以预防与COVID-19相关的结果，包括住院治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Open Forum Infectious Diseases Medicine-Neurology (clinical)

CiteScore

6.70

自引率

4.80%

发文量

630

审稿时长

9 weeks

期刊介绍： Open Forum Infectious Diseases provides a global forum for the publication of clinical, translational, and basic research findings in a fully open access, online journal environment. The journal reflects the broad diversity of the field of infectious diseases, and focuses on the intersection of biomedical science and clinical practice, with a particular emphasis on knowledge that holds the potential to improve patient care in populations around the world. Fully peer-reviewed, OFID supports the international community of infectious diseases experts by providing a venue for articles that further the understanding of all aspects of infectious diseases.